Sagimet Biosciences Inc. (NASDAQ:SGMT)
| Market Cap | 287.70M+21.5% |
| Revenue (ttm) | 0 |
| Net Income | -47.08M+20.7% |
| EPS | -1.28+30.1% |
| Shares Out | 32.58M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 148,910 |
| Open | 8.80 |
| Previous Close | 8.88 |
| Day's Range | 8.71 - 8.86 |
| 52-Week Range | 4.50 - 11.45 |
| Beta | 3.49 |
| Analysts | Buy |
| Price Target | 20.00(+126.50%) |
| Earnings Date | Nov 12, 2026 |
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
About SGMT
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company’s lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer. It also develops TVB-3567, a FASN inhibitor for the treatment of acne indication; and other oncology programs, such as solid tumor and glioblastoma. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$SGMT stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in SGMT holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by SGMT's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
SGMT Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New SGMT patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to SGMT from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in SGMT
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $19.10M |
| IWMiShares Russell 2000 ETF | $13.50M |
| XBIState Street SPDR S&P Biotech ETF | $11.59M |
| VXFVanguard Extended Market ETF | $6.85M |
| IBBiShares Biotechnology ETF | $3.81M |
| IWOiShares Russell 2000 Growth ETF | $3.70M |
Estimated from each fund’s disclosed top holdings × AUM
SGMT Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from SGMT’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score